After earning her law degree from Harvard and her stripes at McKinsey & Company, Mei Mei Hu, J.D., threw herself full tilt into biotech entrepreneurship. From overseeing the launch of one of the first “endobody” vaccines to spinning out five different companies, she has dedicated her career to championing breakthrough medicines and patient access.
Hu, now the CEO of Vaxxinity, is helming a company at the forefront of the medical democratization movement. Vaxxinity, a biotechnology company formed to create a new class of medicines, is in pursuit of a third “biological revolution.” The first, the advent of vaccines, and the second, the pioneering of complex biologics like monoclonal antibodies, have paved the way for a blended approach — a third revolution wherein vaccines are developed to address chronic conditions. In a recent episode of The Business of Biotech, Hu sat down to explore Vaxxinity’s strategy and how traditional vaccines and biologic therapies are converging to improve access to treatment on a global scale.